Hormones and Hormonomimetic Compounds in the Etiology of Cancer

  • Carolyn H. Lingeman
Part of the Recent Results in Cancer Research / Fortschritte der Krebsforschung / Progrès dans les recherches sur le cancer book series (RECENTCANCER, volume 66)

Abstract

Hormones, particularly those produced by the gonads, and their synthetic analogs have been the subject of controversy concerning their roles in the process of carcinogenesis. Experimental evidence, dating from 1916 [118] (Table 1), that estrogens can be potent carcinogens was overlooked or lightly dismissed by many because of a prevalent belief that the body should be able to metabolize these physiologic compounds without toxic effects. The relevance of animal experiments to the human cancer problem was also questioned. During the past four decades, a variety of naturally occurring and synthetic estrogens, progestins, and androgens have been manufactured and prescribed in ever-increasing amounts for replacement, treatment of cancer, prevention of abortion, suppression of lactation, contraception, and other purposes without adequate attention to their carcinogenic potential.

Keywords

Adenocarcinoma Tace Chlorpromazine Graminearum Stilbene 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Adams, N. R.: Pathological changes in the tissues of infertile ewes with clover disease. J. Comp. Pathol. 86, 29–35 (1976)PubMedCrossRefGoogle Scholar
  2. 2.
    Adelman, R. C.: Impaired hormonal regulation of enzyme activity during aging. Fed. Proc. 34, 179–182 (1975)PubMedGoogle Scholar
  3. 3.
    Adlercreutz, H., Tenhunen, R.: Some aspects of the interaction between natural and synthetic female sex hormones and the liver. Am. J. Med. 49, 630–648 (1970)PubMedCrossRefGoogle Scholar
  4. 4.
    Akazaki, K., Stemmermann, G. N.: Comparative study of latent carcinoma of the prostate among Japanese in Japan and Hawaii. J. Natl. Cancer Inst. 50, 1137–1144 (1973)PubMedGoogle Scholar
  5. 5.
    Apostolakis, M., Kapetanakis, S., Lazos, G., Madena-Pyrgaki, A.: Plasma prolactin activity in male and female patients lactating due to psychotropic drug administration. Acta Endocrinol. Suppl. 155, 19 (1971) (Abstract)Google Scholar
  6. 6.
    Arcos, J. C., Argus, M. F.: Chemical Induction of Cancer. Vol. IIA. New York and London: Academic Press, 1974aGoogle Scholar
  7. 7.
    Arcos, J. C., Argus, M. F.: Chemical Induction of Cancer. Vol. IIB. New York and London: Academic Press, 1974bGoogle Scholar
  8. 8.
    Armenian, H. K., Lilienfeld, A. M., Diamond, E. L., Bross, I. D. J.: Relation between benign prostatic hyperplasia and cancer of the prostate. Lancet 2, 115–117 (1974)PubMedCrossRefGoogle Scholar
  9. 9.
    Armstrong, B., Stevens, N., Doll, R.: Retrospective study of the association between use of rauwolfia derivatives and breast cancer in English women. Lancet 2, 672–675 (1974)PubMedCrossRefGoogle Scholar
  10. 10.
    Ashley, D. J. B.: A male-female differential in tumour incidence. Br. J. Cancer 23, 21–25 (1969)PubMedCrossRefGoogle Scholar
  11. 11.
    Barraclough, C. A.: Blockade of the release of pituitary gonadotropin by reserpine. Fed. Proc. 14, 9–10 (1955)Google Scholar
  12. 12.
    Baum, J. K., Holtz, F., Bookstein, J. J., Klein, E. W.: Possible association between benign hepatomas and oral contraceptives. Lancet 2, 926–929 (1973)PubMedCrossRefGoogle Scholar
  13. 13.
    Beatson, G. T.: On the treatment of inoperable cases of carcinoma of the mamma: Suggestion for a new method of treatment with illustrative cases. Lancet 2, 104–107 (1896)CrossRefGoogle Scholar
  14. 14.
    Bern, H. A., Jones, L. A., Mills, K. T., Kohrman, A., Mori, T.: Use of the neonatal mouse in studying longterm effects of early exposure to hormones and other agents. J. Toxicol. Environ. Health Suppl. 1, 103–116 (1976)PubMedGoogle Scholar
  15. 15.
    Beumont, P. J. V., Harris, G. W., Carr, P. J., Friesen, H. G., Kolakowska, T., Mackinnon, P. C. B., Mandelbrote, B. M., Wiles, D.: Some endocrine effects of phenothiazines; a preliminary report. J. Psychosom. Res. 16, 297–304 (1972)PubMedCrossRefGoogle Scholar
  16. 16.
    Bibbo, M., Gill, W. B., Azizi, F., Blough, R., Fang, V. S., Rosenfield, R. L., Schumacher, G. F. B., Sleeper, K., Sonek, M. G., Wied, G. L.: Follow-up study of male and female offspring of DES-exposed mothers. Obstet. Gynecol. 49, 1–8 (1977)PubMedGoogle Scholar
  17. 17.
    Bickoff, E. M., Booth, A. N., Lyman, R. L., Livingston, A. L., Thompson, C. R., Deeds, F.: Coumestrol, a new estrogen isolated from forage crops. Science 126, 969–970 (1957)PubMedCrossRefGoogle Scholar
  18. 18.
    Bickoff, E. M., Livingston, A. L., Hendrickson, A. P., Booth, A. N.: Relative potencies of several estrogenlike compounds found in forages. J. Agric. Food Chem. 10, 410–412 (1962)CrossRefGoogle Scholar
  19. 19.
    Bird, D. R., Vowles, K. D. J.: Liver damage from long term methyltestosterone. Lancet 2, 400–401 (1977)PubMedCrossRefGoogle Scholar
  20. 20.
    Bitman, J., Cecil, H. C.: Estrogenic activity of DDT analogs and polychlorinated biphenyls. J. Agric. Food Chem. 18, 1108–1112 (1970)PubMedCrossRefGoogle Scholar
  21. 21.
    Bolande, R. P.: Childhood tumors and their relationship to birth defects. In Genetics of Human Cancer. Mulvihill, J. J., Miller, R. W., Fraumeni, J. F., Jr. (Eds.). New York: Raven Press, 1977Google Scholar
  22. 22.
    Boston Collaborative Drug Program. Reserpine and breast cancer. Lancet 2, 669–671 (1974)Google Scholar
  23. 23.
    Bradbury, R. B., White, D. E.: Estrogens and related substances in plants. Vitam. Horm. 12, 207–233 (1954)PubMedCrossRefGoogle Scholar
  24. 24.
    Brooks, S. C.: The metabolism of steroid hormones in breast cancer: A reappraisal. Curr. Top. Mol. Endocrinol. 4, 36–50 (1976)PubMedGoogle Scholar
  25. 25.
    Budzynska, A., Wasikowa, R., Zajac, J.: Hyperestrogenism in children of employees of the Polfa Pharmaceutical Laboratories in Jenenia Gora. Pol. Med. J. 6, 1249–1256 (1967)PubMedGoogle Scholar
  26. 26.
    Buell, P.: Changing incidence of breast cancer in Japanese-American women. J. Natl. Cancer Inst. 51, 1479–1483 (1973)PubMedGoogle Scholar
  27. 27.
    Buell, P., Dunn, J. E.: Cancer mortality among Japanese issei and nisei of California. Cancer 18, 656–664 (1965)PubMedCrossRefGoogle Scholar
  28. 28.
    Burbank, F.: Patterns in Cancer Mortality in the United States: 1950–1967. Natl. Cancer Inst. Monogr. 33, 307 (1971)Google Scholar
  29. 29.
    Carcinogenicity Testing of Oral Contraceptives. Report by the Committee on Safety of Medicines. London: Her Majesty’s Stationery Office, 1972Google Scholar
  30. 30.
    Chen, H. J., Bradley, C. J., Meites, J.: Stimulation of growth of carcinogen-induced mammary cancers in rats by thyrotropin-releasing hormone. Cancer Res. 37, 64–66 (1977)PubMedGoogle Scholar
  31. 31.
    Chu, E. W., Salmon, M. J.: Observations on vaginal cornification in patients resident in a mental hospital. Am. J. Obstet. Gynecol. 83, 165–170 (1962)PubMedGoogle Scholar
  32. 32.
    Clemens, J. A., Smalstig, E. B., Sawyer, B. D.: Antipsychotic drugs stimulate prolactin release. Psychopharmacologia (Berl.) 40, 123–127 (1974)CrossRefGoogle Scholar
  33. 33.
    Conney, A. H., Burns, J. J.: Metabolic interactions among environmental chemicals and drugs. Science 178, 576–586 (1972)PubMedCrossRefGoogle Scholar
  34. 34.
    Corbett, D. G., Abrams, E. W.: Bilateral carcinoma of the male breast associated with prolonged stilbestrol therapy for carcinoma of the prostate. J. Urol. 64, 377–381 (1950)PubMedGoogle Scholar
  35. 35.
    Costlow, M. E., McGuire, W. L.: Autoradiographic localization of prolactin receptors in 7,12-dimethylbenz[a]anthracene-induced rat mammary carcinoma. J. Natl. Cancer Inst. 58, 1173–1175 (1977)PubMedGoogle Scholar
  36. 36.
    Cutler, B. S., Forbes, A. P., Ingersoll, F. M., Scully, R. E.: Endometrial carcinoma after stilbestrol therapy in gonadal dysgenesis. New Engl. J. Med. 287, 628–631 (1972)PubMedCrossRefGoogle Scholar
  37. 37.
    Dao, T. L., Morreal, C., Nemoto, T.: Urinary estrogen excretion in men with breast cancer. New Engl. J. Med. 289, 138–140 (1973)PubMedCrossRefGoogle Scholar
  38. 38.
    Dean, L., Abell, D. A., Beischer, N. A.: Incidence of anencephaly and other major malformations when oestriol excretion is very low. Br. Med. J. 1, 257–258 (1977)PubMedCrossRefGoogle Scholar
  39. 39.
    Diczfalusy, E.: Recent progress in the fetoplacental metabolism of steroids. In: Reproductive Endocrinology. Vokaer, R., DeBock, G. (Eds.). New York: Pergamon Press, 1975, p. 3Google Scholar
  40. 40.
    Dodds, E. C., Golberg, L., Lawson, W., Robinson, R.: Oestrogenic activity of certain synthetic compounds. Nature (London) 141, 247–248 (1938)CrossRefGoogle Scholar
  41. 41.
    Doisy, E. A., Veler, C. D., Thayer, S.: Folliculin from urine of pregnant women. Am. J. Physiol. 90, 329–330 (1929)Google Scholar
  42. 42.
    Dunn, J. E., Jr., Bragg, K. U., Sautter, C., Gardipee, C.: Breast cancer risk following a major salivary gland carcinoma. Cancer 29, 1343–1346 (1972)PubMedCrossRefGoogle Scholar
  43. 43.
    Dunn, T. B.: Cancer of the uterine cervix in mice fed a liquid diet containing an antifertility drug. J. Natl. Cancer Inst. 43, 671–692 (1969)PubMedGoogle Scholar
  44. 44.
    Dunn, T. B., Green, A. W.: Cysts of the epididymis, cancer of the cervix, granular cell myoblastoma, and other lesions after estrogen injection in newborn mice. J. Natl. Cancer Inst. 31, 425–455 (1963)PubMedGoogle Scholar
  45. 45.
    Edgren, R. A.: Are oral contraceptives and diethylstilbestrol (DES) involved in sex-linked cancer? Curr. Top. Mol. Endocrinol. 4, 95–106 (1976)PubMedGoogle Scholar
  46. 46.
    Editorial: Cyproterone acetate. Lancet 1, 1003–1004 (1976)Google Scholar
  47. 47.
    Edmondson, H. A.: Tumors of the Gallbladder and Extrahepatic Bile Ducts. In: Atlas of Tumor Pathology, Section VII, Fascicle 26. Washington, D.C.: Armed Forces Inst. Pathol., 1967Google Scholar
  48. 48.
    Eideisberg, J.: Estrogens in urine and cytology of vaginal smears after the use of an estrogenic cream. Am. J. Med. Sci. 214, 630–632 (1947)CrossRefGoogle Scholar
  49. 49.
    Eisenfeld, A. J., Aten, R., Weinberger, M., Haselbacher, G., Halpern, K., Krakoff, L.: Estrogen receptor in the mammalian liver. Science 191, 862–865 (1976)PubMedCrossRefGoogle Scholar
  50. 50.
    Everson, R. B., Li, F. P., Fraumeni, J. F., Jr., Fishman, J., Wilson, R. E., Stout, D., Norris, H. J.: Familial male breast cancer. Lancet 1, 9–12 (1976)PubMedCrossRefGoogle Scholar
  51. 51.
    Faber, L. E., Saffran, J., Chen, T. J., Leavitt, W. W.: Mammalian progesterone receptors: Biosynthesis, structure and nuclear binding. Curr. Top. Mol. Endocrinol. 4, 68–84 (1976)PubMedGoogle Scholar
  52. 52.
    Farrell, G. C., Joshua, D. E., Uren, R. F., Baird, P. J., Perkins, K. W., Kronerberg, H.: Androgen-induced hepatoma. Lancet 1, 430–432 (1975)PubMedCrossRefGoogle Scholar
  53. 53.
    Fechner, R. E.: Carcinoma of the breast during estrogen replacement therapy. Cancer 29, 566–573 (1972)PubMedCrossRefGoogle Scholar
  54. 54.
    Fechner, R. E.: Influence of oral contraceptives on breast diseases. Cancer 39, 2764–2771 (1977)PubMedCrossRefGoogle Scholar
  55. 55.
    Festing, M., Staats, J.: Standardized nomenclature for inbred strains of rats. Transplantation 16, 221–245 (1973)CrossRefGoogle Scholar
  56. 56.
    Fitzsimons, M. P.: Gynaecomastia in stilboestrol workers. Br. J. Ind. Med. 1, 235–237 (1945)Google Scholar
  57. 57.
    Forsberg, J.-G.: Derivation and differentiation of the vaginal epithelium. Lund, The Institute of Anatomy (Thesis), 1963Google Scholar
  58. 58.
    Forsberg, J.-G.: Induction of conditions leading to cancer in the genital tract by estrogen during the differentiation phase of the genital epithelium. Adv. Biosci. 13, 139–151 (1974)PubMedGoogle Scholar
  59. 59.
    Forsberg, J.-G.: Animal model: Estrogen-induced adenosis of vagina and cervix in mice. Am. J. Pathol. 84, 669–672 (1976)PubMedGoogle Scholar
  60. 60.
    Fotherby, K.: Metabolism of synthetic steroids by animals and man. Acta Endocrinol. Suppl. 185, 119–147 (1974)Google Scholar
  61. 61.
    Foulds, L.: Neoplastic Development, Vol. 2. New York: Academic Press, 1975Google Scholar
  62. 62.
    Fraumeni, J. F., Lloyd, J. W., Smith, E. M., Wagoner, J. K.: Cancer mortality among nuns: Role of marital status in etiology of neoplastic disease in women. J. Natl. Cancer Inst. 42, 455–468 (1969)PubMedGoogle Scholar
  63. 63.
    Furth, J.: Recent experimental studies on leukosis. Physiol. Rev. 26, 47–76 (1946)PubMedGoogle Scholar
  64. 64.
    Gardner, W. U., Allen, E.: Malignant and non-malignant uterine and vaginal lesions in mice receiving estrogens and estrogens and androgens simultaneously. Yale J. Biol. Med. 12, 213–234 (1939)PubMedGoogle Scholar
  65. 65.
    Gardner, W. U., Pan, S. C.: Malignant tumors of the uterus and vagina in untreated mice of the PM stock. Cancer Res. 8, 241–256 (1948)PubMedGoogle Scholar
  66. 66.
    Gardner, W. U., Dougherty, T. F., Williams, W. L.: Lymphoid tumors in mice receiving steroid hormones. Cancer Res. 4, 73–87 (1944)Google Scholar
  67. 67.
    Gaunt, R., Renzi, A. A., Antonchak, N., Miller, G. J., Gilman, M.: Endocrine aspects of the pharmacology of reserpine. Ann. N.Y. Acad. Sci. 59, 22–35 (1954)PubMedCrossRefGoogle Scholar
  68. 68.
    Gillette, J. R., Stripp, B.: Pre- and postnatal enzyme capacity for drug metabolite production. Fed. Proc. 34, 172–178 (1975)PubMedGoogle Scholar
  69. 69.
    Grandison, L., Guidotti, A.: Regulation of prolactin release by endogenous opiates. Nature (London) 270, 357–359 (1977)CrossRefGoogle Scholar
  70. 70.
    Greenblatt, D.J., Koch-Weser, J.: Adverse reactions to spironolactone. A report from the Boston Collaborative Drug Surveillance Program. J. Am. Med. Assoc. 225, 40–43 (1973)CrossRefGoogle Scholar
  71. 71.
    Greenblatt, R. B., Brown, N. H.: The storage of estrogen in human fat after estrogen administration. Am. J. Obstet. Gynecol. 63, 1361–1363 (1952)PubMedGoogle Scholar
  72. 72.
    Greene, H. S. N.: Diseases of the rabbit. In: Pathology of Laboratory Animals. Ribelin, W. E., McCoy, J. R. (Eds.). Springfield: Charles C. Thomas, 1965, p. 330Google Scholar
  73. 73.
    Grumbach, M. M.: Gonads. Sex determination and sex differentiation. In: Textbook of Medicine. Beeson, P.B., McDermott, W. (Eds.). Philadelphia and London: W. B. Saunders Co., 1963, p. 1407Google Scholar
  74. 74.
    Gupta, R. L.: Carcinoma of the breast in a case of Klinefelter syndrome. Indian J. Cancer 3, 184–189 (1966)PubMedGoogle Scholar
  75. 75.
    Gustafsson, J., Stenberg, A.: Partial masculinization of rat liver enzyme activities following treatment with FSH. Endocrinology 96, 501–504 (1975)PubMedCrossRefGoogle Scholar
  76. 76.
    Hadler, H. I.: Reserpine and chemical carcinogenesis. Lancet 1, 169 (1975)PubMedCrossRefGoogle Scholar
  77. 77.
    Haenszel, W., Kurihara, M.: Studies of Japanese migrants. I. Mortality from cancer and other diseases among Japanese in the United States. J. Natl. Cancer Inst. 40, 43–68 (1968)PubMedGoogle Scholar
  78. 78.
    Harmon, J., Aliapoulios, M. A.: Gynecomastia in marijuana users. New Engl. J. Med. 287, 936 (1972)PubMedGoogle Scholar
  79. 79.
    Harry, R. G.: Modern Cosmetology, Vol. 1. New York: Chemical Publishing Co., 1968Google Scholar
  80. 80.
    Harwig, J., Munro, I. C.: Mycotoxins of possible importance in diseases of Canadian farm animals. Can. Vet. J. 16, 125–139 (1975)Google Scholar
  81. 81.
    Hausknecht, R. U., Gusberg, S. B.: Estrogen metabolism in patients at high risk for endometrial carcinoma. Am. J. Obstet. Gynecol. 116, 981–984 (1973)PubMedGoogle Scholar
  82. 82.
    Heath, E. C., Dingell, J. V.: The interaction of foreign chemical compounds with the glucuronidation of estrogens in vitro. Drug Metab. Dispos. 2, 556–565 (1974)PubMedGoogle Scholar
  83. 83.
    Heinonen, O. P., Shapiro, S., Tuonimen, L., Turunen, M. I.: Reserpine use in relation to breast cancer. Lancet 2, 675–677 (1974)PubMedCrossRefGoogle Scholar
  84. 84.
    Heinonen, O. P., Slone, D., Monson, R. R., Hook, E. B., Shapiro, S.: Cardiovascular birth defects and antenatal exposure to female sex hormones. New Engl. J. Med. 296, 67–70 (1977)PubMedCrossRefGoogle Scholar
  85. 85.
    Helton, E. D., Goldzieher, J. W.: The pharmacokinetics of ethynyl estrogens. A review. Contraception 15, 255–284 (1977)PubMedCrossRefGoogle Scholar
  86. 86.
    Henderson, B. E., Gerkins, V. R., Pike, M. C.: Sexual factors and pregnancy. In: Persons at High Risk of Cancer. Fraumeni, J. F. (Ed.). New York: Academic Press, Inc., 1975, p. 267Google Scholar
  87. 87.
    Herbst, A. L., Ulfelder, H., Poskanzer, D. C.: Adenocarcinoma of the vagina. Association of maternal stilbestrol therapy with tumor appearance in young women. New Engl. J. Med. 284, 878–881 (1971)PubMedCrossRefGoogle Scholar
  88. 88.
    Hertig, A. T., Gore, H.: Tumors of the female sex organs. Part 2. Tumors of the vulva, vagina and uterus. In: Atlas of Tumor Pathology, Section IX, Fascicle 33. Washington, D.C.: Armed Forces Inst. of Pathol., 1960Google Scholar
  89. 89.
    Hertz, R.: Steroid-induced, steroid-producing, and steroid-responsive tumors. Curr. Top. Mol. Endocrinol. 4, 1–14 (1976)PubMedGoogle Scholar
  90. 90.
    Heston, W. E., Vlahakis, G., Desmukes, B.: Effects of the antifertility drug Enovid in five strains of mice, with particular regard to carcinogenesis. J. Natl. Cancer Inst. 51, 209–224 (1973)PubMedGoogle Scholar
  91. 91.
    Hill, M. J., Goddard, P., Williams, R. E. O.: Gut bacteria and etiology of cancer of the breast. Lancet 2, 472–473 (1971)PubMedCrossRefGoogle Scholar
  92. 92.
    Hoover, R., Fraumeni, J. F., Jr., Everson, R., Myers, M. H.: Cancer of the uterine corpus after hormonal treatment for breast cancer. Lancet 1, 885–887 (1976)PubMedCrossRefGoogle Scholar
  93. 93.
    Hoover, R., Gray, L. A., Cole, P., MacMahon, B.: Menopausal estrogens and breast cancer. New Engl. J. Med. 295, 401–405 (1976)PubMedCrossRefGoogle Scholar
  94. 94.
    Hoover, R., Gray, L. A., Sr., Fraumeni, J. F.: Stilboestrol (diethylstilboestrol) and the risk of ovarian cancer. Lancet 2, 533–534 (1977)PubMedCrossRefGoogle Scholar
  95. 95.
    Huseby, R. A.: Estrogen-induced Leydig cell tumor in the mouse: A model system for the study of carcinogenesis and hormone dependency. J. Toxicol. Environ. Health, Suppl. 1, 177–192 (1976)Google Scholar
  96. 96.
    Ingelfinger, F. J.: Gallstones and estrogens. New Engl. J. Med. 290, 51–52 (1974)PubMedCrossRefGoogle Scholar
  97. 97.
    International Agency for Research on Cancer. IARC Monographs on the Evaluation of Carcinogenic Risk of Chemicals to Man. Sex Hormones, Vol. 6. Lyon: International Agency for Research on Cancer, 1974Google Scholar
  98. 98.
    International Agency for Research on Cancer, World Health Organization. Cancer Incidence in Five Continents, Vol. III. Waterhouse, J., Muir, C., Correa, P., Powell, J. (Eds.). IARC Scientific Publications No. 15. Lyon: International Agency for Research on Cancer, 1976Google Scholar
  99. 99.
    Jackson, A. W., Muldal, S., Ockey, C. H., O’Connor, P. J.: Carcinoma of male breast in association with the Klinefelter syndrome. Br. Med. J. 1, 223–225 (1965)PubMedCrossRefGoogle Scholar
  100. 100.
    Jasmin, G., Riopelle, J. L.: Nephroblastomas induced in ovariectomized rats by dimethylbenzanthracene. Cancer Res. 30, 321–326 (1970)PubMedGoogle Scholar
  101. 101.
    Joly, D., Lilienfeld, A. J., Diamond, E. L., Bross, I. D.: An epidemiologic study of the relationship of reproductive experience with cancer of the ovary. Am. J. Epidemiol. 99, 190–209 (1974)PubMedGoogle Scholar
  102. 102.
    Jones, L. A., Bern, H. A.: Long-term effects of neonatal treatment with progesterone, alone and in combination with estrogen, on the mammary gland and reproductive tract of female BALB/cfC3H mice. Cancer Res. 37, 67–75 (1977)PubMedGoogle Scholar
  103. 103.
    Jørgensen, P. I.: Low urinary oestriol excretion during pregnancy in women giving birth to infants with Down’s syndrome. Lancet 2, 782–783 (1972)PubMedCrossRefGoogle Scholar
  104. 104.
    Kaplan, N. M.: Male pseudohermaphrodism. Report of a case with observations on pathogenesis. New Engl. J. Med. 261, 641–644 (1959)PubMedCrossRefGoogle Scholar
  105. 105.
    Kimura, T., Nandi, S.: Nature of induced persistent vaginal cornification in mice. IV. Changes in the vaginal epithelium of old mice treated neonatally with estradiol or testosterone. J. Natl. Cancer Inst. 39, 75–93 (1967)PubMedGoogle Scholar
  106. 106.
    King, N. W.: Comparative pathology of the uterus. In: The Uterus. Norris, H. J., Hertig, A. T., Abel, M. R. (Eds.). Baltimore: Williams and Wilkins, 1973, p. 489Google Scholar
  107. 107.
    Kirschner, M. A.: The role of hormones in the etiology of human breast cancer. Cancer 39, 2716–2726 (1977)PubMedCrossRefGoogle Scholar
  108. 108.
    Kling, R. E., Lazar, A.: The development of a radioimmunometric assay for diethylstilbestrol in tissues: Part I. FDA By-Lines, No. 2, September 1976, p. 65Google Scholar
  109. 109.
    Kodama, M., Kodama, T., Totani, R.: Hormonal status of cervical cancer. J. Natl. Cancer Inst. 59, 41–47 (1977)PubMedGoogle Scholar
  110. 110.
    Koo, G. C., Wachtel, S. S., Saenger, P., New, M. I., Dosik, H., Amarose, A. P., Dorus, E., Ventruto, V.: H-Y Antigen: Expression in human subjects with the testicular feminization syndrome. Science 196, 655–656 (1977)PubMedCrossRefGoogle Scholar
  111. 111.
    Koss, L. G.: Diagnostic Cytology and its Histopathologic Bases. Philadelphia: Lippincott, 1968Google Scholar
  112. 112.
    Kupfer, D., Bulger, W. H.: Interactions of chlorinated hydrocarbons with steroid hormones. Fed. Proc. 35, 2603–2608 (1976)PubMedGoogle Scholar
  113. 113.
    Lacassagne, A.: Sarcomes lymphoides apparus chez des souris longuement traitées par des hormones oestrogenes. C.R. Soc. Biol. Paris 126, 193–195 (1937)Google Scholar
  114. 114.
    Lacassagne, A.: Effets opposés de l’iproniazide et de la resérpine, sur la cancérisation du foie du rat par p-dimethylaminoazobenzene. C.R. Acad. Sci. Paris 263, 701–703 (series D) (1966)Google Scholar
  115. 115.
    Lacassagne, A., Duplan, J.-F.: Le mécanisme de la cancérisation de la mamelle chez la souris, consideré d’apres les résultats d’experiences au moyen de la reserpine. Compt. Rend. 249, 810–812 (1959)Google Scholar
  116. 116.
    Lacassagne, A., Hurst, L., Rosenberg, A.-J.: Influence de la chlorpromazine et de la reserpine sur la cancerisation experimentale du foie chez le rat. Compt. Rend. 249, 903–905 (1959)Google Scholar
  117. 117.
    Lacassagne, M. A.: Apparition de cancers de la mamelle chez la souris mâle, soumise à des injections de folliculine. Compt. Rend. Acad. Sci. 195, 630–632 (1932)Google Scholar
  118. 118.
    Lathrop, A. E. C., Loeb, L.: Further investigations on the origin of tumors in mice. III. On the part played by internal secretion in the spontaneous development of tumors. J. Cancer Res. 1, 1–19 (1916)PubMedGoogle Scholar
  119. 119.
    Leonard, B. J.: The use of rodents for studies of toxicity in contraceptive research. Acta Endocrinol. Suppl. 185, 34–73 (1974)Google Scholar
  120. 120.
    Leopold, A. S., Erwin, M., Oh, J., Browning, B.: Phytoestrogens: Adverse effects on reproduction in California quail. Science 191, 98–100 (1976)PubMedCrossRefGoogle Scholar
  121. 121.
    LeWinn, E. B.: Gynecomastia during digitalis therapy. New Engl. J. Med. 248, 316–320 (1953)PubMedCrossRefGoogle Scholar
  122. 122.
    Lewis, R. M.: The clinical use of stilbestrol, a synthetic estrogen. Preliminary report. Yale J. Biol. Med. 12, 235–238 (1939)PubMedGoogle Scholar
  123. 123.
    Liao, S., Hung, S. C., Tymoczko, J. L., Liang, T.: Active forms and biodynamics of the androgen-receptor in various target tissues. Curr. Top. Mol. Endocrinol. 4, 139–151 (1976)PubMedGoogle Scholar
  124. 124.
    Licata, A. A., Bartter, F. C.: Spironolactone-induced gynaecomastia related to allergic reaction to ‘Darvon compound’. Lancet 2, 905 (1976)PubMedCrossRefGoogle Scholar
  125. 125.
    Lilienfeld, A. M.: Possible existence or predisposing factors in the etiology of selected cancers of non-sexual sites in females: A preliminary inquiry. Cancer 9, 111–122 (1956)PubMedCrossRefGoogle Scholar
  126. 126.
    Lingeman, C. H.: Liver-cell neoplasms and oral contraceptives. Lancet 1, 64 (1974a)PubMedCrossRefGoogle Scholar
  127. 127.
    Lingeman, C. H.: Etiology of cancer of the ovary: A review. J. Natl. Cancer Inst. 53, 1603–1618 (1974b)PubMedGoogle Scholar
  128. 128.
    Lippman, M., Barr, R.: Glucocorticoid receptors in purified subpopulations of human peripheral blood lymphocytes. J. Immunol. 118, 1977–1981 (1977)PubMedGoogle Scholar
  129. 129.
    Lippman, M. E., Osborne, C. K., Knazek, R., Young, N.: In vitro model systems for the study at hormone-dependent human breast cancer. New Engl. J. Med. 296, 154–159 (1977)PubMedCrossRefGoogle Scholar
  130. 130.
    Loube, S. D., Quirk, R. A.: Breast cancer associated with administration of spironolactone. Lancet 1, 1428–1429 (1975)PubMedCrossRefGoogle Scholar
  131. 131.
    Lyon, F. A.: Development of adenocarcinoma of endometrium in young women receiving long-term sequential oral contraception. Am. J. Obstet. Gynecol. 123, 299–301 (1975)PubMedGoogle Scholar
  132. 132.
    Mack, T. M., Henderson, B. E., Gerkins, V. R., Arthur, M., Baptista, J., Pike, M. C.: Reserpine and breast cancer in a retirement community. New Engl. J. Med. 292, 1366–1371 (1975)PubMedCrossRefGoogle Scholar
  133. 133.
    MacMahon, B., Austin, J. H.: Association of carcinomas of breast and corpus uteri. Cancer 23, 275–280 (1969)PubMedCrossRefGoogle Scholar
  134. 134.
    MacMahon, B., Cole, P., Brown, J.: Etiology of human breast cancer: A review. J. Natl. Cancer Inst. 50, 21–42 (1973)PubMedGoogle Scholar
  135. 135.
    Mainwaring, W. I. P.: The relevance of studies on androgen action to prostatic cancer. Curr. Top. Mol. Endocrinol. 4, 152–171 (1976)PubMedGoogle Scholar
  136. 136.
    McCarty, K. S., Jr., McCarty, K. S.: Steroid hormone receptors in the regulation of differentiation. A review. Am. J. Pathol. 86, 703–744 (1977)Google Scholar
  137. 137.
    McGuire, W. L., Horwitz, K. B., Pearson, O. H., Segaloff, A.: Current status of estrogen and progesterone receptors in breast cancer. Cancer 39, 2934–2947 (1977)PubMedCrossRefGoogle Scholar
  138. 138.
    McKinney, G. R., Weikel, J. H., Webb, W. K., Dick, R. G.: Use of life-table techniques to estimate effects of certain steroids on probability of tumor formation in a long term study in rats. Toxicol. Appl. Pharmacol. 12, 68–79 (1968)PubMedCrossRefGoogle Scholar
  139. 139.
    McLachlan, J. A.: Transplacental toxicity of diethylstilbestrol: A special problem in safety evaluation. Adv. Modern Toxicol. 1, 423–448 (1976)Google Scholar
  140. 140.
    McLachlan, J. A., Newbold, R. R., Bullock, B.: Reproductive tract lesions in male mice exposed prenatally to diethylstilbestrol. Science 190, 991–992 (1975)PubMedCrossRefGoogle Scholar
  141. 141.
    McLean, A. E. M.: Enzyme induction in the fetus and the role of enzyme induction in the localization of carcinogenesis. In: Transplacental Carcinogenesis. Tomatis, L., Mohr, U. (Eds.). Lyon: International Agency for Research on Cancer, 1973Google Scholar
  142. 142.
    Meissner, W. A., Sommers, S. C., Sherman, G.: Endometrial hyperplasia, endometrial carcinoma and endometriosis produced experimentally by estrogen. Cancer 10, 500–509 (1957)PubMedCrossRefGoogle Scholar
  143. 143.
    Meltzer, H. Y., Sachar, E. J., Frantz, A. G.: Dopamine antagonism by thioridazine in schizophrenia. Biol. Psychiatry 10, 53–57 (1975)Google Scholar
  144. 144.
    The Merck Index, 9th Ed., Windholz, M. (Ed.). Rahway: Merck and Co., 1976Google Scholar
  145. 145.
    Migaki, G., Carey, A. M., Turnquest, R. U., Garner, F. M.: Pathology of bovine uterine adenocarcinoma. J. Am. Vet. Med. Assoc. 157, 1577–1584 (1970)PubMedGoogle Scholar
  146. 146.
    Mirocha, C. J., Christensen, C. M., Nelson, G. H.: Physiologic activity of some fungal estrogens produced by Fusarium. Cancer Res. 28, 2319–2322 (1968)PubMedGoogle Scholar
  147. 147.
    Moore, C. R., Lamar, J. K., Beck, N.: Cutaneous absorption of sex hormones. J. Am. Med. Assoc. 111, 11–14 (1938)CrossRefGoogle Scholar
  148. 148.
    Mostofi, F. K., Leestma, J. E.: Lower urinary tract and male genitalia. In: Pathology, sixth edition, Vol. 1. Anderson, W. A. D. (Ed.). St. Louis: C.V. Mosby, 1971, p. 828Google Scholar
  149. 149.
    Mostofi, F. K., Price, E. B: Tumors of the male genital system. In: Atlas of Tumor Pathology, second series, Fascicle 8. Washington, D.C.: Armed Forces Inst. Pathol., 1973Google Scholar
  150. 150.
    Mulvihill, J. J.: Congenital and genetic diseases. In: Persons at High Risk of Cancer. Fraumeni, J. F. (Ed.). New York: Academic Press, 1975, p. 3Google Scholar
  151. 151.
    Murphy, E. D.: Carcinogenesis of the uterine cervix in mice. Effect of diethylstilbesterol after limited application of 3-methylcholanthrene. J. Natl. Cancer Inst. 27, 611–653 (1961)PubMedGoogle Scholar
  152. 152.
    Murphy, E. D.: Carcinogenesis of the uterine cervix in mice: Effect of castration after limited application of 3-methylcholanthrene. J. Natl. Cancer Inst. 41, 1111–1116 (1968)PubMedGoogle Scholar
  153. 153.
    Nadell, J., Kosek, J.: Peliosis hepatis. Twelve cases associated with oral androgen therapy. Arch. Pathol. Lab. Med. 101, 405–410 (1977)PubMedGoogle Scholar
  154. 154.
    Nelson, G. H., Christensen, C. M., Mirocha, C.: Fusarium and estrogenism in swine. J. Am. Vet. Med. Assoc. 163, 1276–1277 (1973)PubMedGoogle Scholar
  155. 155.
    Neumann, F., Graf, K. J.: Discovery, development, mode of action and clinical uses of cyproterone acetate. J. Int. Med. Res. 3 (Suppl. 4), 1–9 (1975)Google Scholar
  156. 156.
    Nicolis, G. L., Sabetghadam, R., Hsu, C. C. S., Sohval, A. R., Gabrilove, J. L.: Breast cancer after mumps orchitis. J. Am. Med. Assoc. 223, 1032–1033 (1973)CrossRefGoogle Scholar
  157. 157.
    Noble, R. L.: The development of prostatic adenocarcinoma in Nb rats following prolonged sex hormone administration. Cancer Res. 37, 1929–1933 (1957)Google Scholar
  158. 158.
    Noble, R. L.: A new approach to the hormonal cause and control of experimental carcinomas, including those of the breast. Ann. R. Coll. Phys. Surg. Can. 9, 169–180 (1976)Google Scholar
  159. 159.
    Noble, R. L.: Hormonal control of growth and progression in tumors of Nb rats and a theory of action. Cancer Res. 37, 82–94 (1977)PubMedGoogle Scholar
  160. 160.
    Nomura, T., Kanzaki, T.: Induction of urogenital anomalies and some tumors in the progeny of mice receiving diethylstilbestrol during pregnancy. Cancer Res. 37, 1099–1104 (1977)PubMedGoogle Scholar
  161. 161.
    Nomura, Y., Kobayashi, S., Takatani, O., Sugano, H., Matsumoto, K., McGuire, W. L.: Estrogen receptor and endocrine responsiveness in Japanese versus American breast cancer patients. Cancer Res. 37, 106–110 (1977)PubMedGoogle Scholar
  162. 162.
    Norris, H. J., Taylor, H. B.: Carcinoma of the male breast. Cancer 23, 1428–1435 (1969)PubMedCrossRefGoogle Scholar
  163. 163.
    O’Fallon, W. M., Labarthe, D. R., Kurland, L. T.: Rauwolfia derivatives and breast cancer. Lancet 2, 292–300 (1975)PubMedCrossRefGoogle Scholar
  164. 164.
    O’Shea, J. D., Jabara, A. G.: The histogenesis of canine ovarian tumours induced by stilboestrol administration. Pathol. Vet. 4, 137–148 (1967)PubMedGoogle Scholar
  165. 165.
    Otten, J., Smets, R., Jager, R. de, Gerard, A., Maurus, R.: Hepatoblastoma in an infant after contraceptive intake during pregnancy. New Engl. J. Med. 297, 222 (1977)PubMedGoogle Scholar
  166. 166.
    Overholser, M. D., Allen, E.: Atypical growth induced in cervical epithelium of the monkey by prolonged injection of ovarian hormone combined with chronic trauma. Surg. Gynecol. Obstet. 60, 129–136 (1935)Google Scholar
  167. 167.
    Persijn, R. P., Korsten, C. B., Engelsman, E.: Oestrogen and androgen receptors in breast cancer. Br. Med. J. 4, 503 (1975)PubMedCrossRefGoogle Scholar
  168. 168.
    Petit, P., Engels, J.: Low maternal oestriol excretion and congenital chromosome abnormalities. Lancet 2, 970 (1972)PubMedCrossRefGoogle Scholar
  169. 169.
    Physicians Desk Reference, 31st Edition. Oradell, N. J., Medical Economics Co., 1977Google Scholar
  170. 170.
    Pollard, M., Luckert, P. H.: Transplantable metastasizing prostate adenocarcinomas in rats. J. Natl. Cancer Inst. 54, 643–649 (1975)PubMedGoogle Scholar
  171. 171.
    Poortman, J., Prenan, J. A. C., Schwarz, F., Thijssen, J. H. H.: Interaction of Δ5-androstene-3β, 17β-diol with estradiol and dihydrotestosterone receptors in human myometrial and mammary cancer tissue. J. Clin. Endocrinol. Metab. 40, 373–379 (1975)PubMedCrossRefGoogle Scholar
  172. 172.
    Pryor, A. C., Cohen, R. J., Goldman, R. L.: Hepatocellular carcinoma in a woman on long term oral contraceptives. Cancer 40, 884–888 (1977)PubMedCrossRefGoogle Scholar
  173. 173.
    Rogers, P. C., Komp, D., Rogol, A., Sabio, H.: Possible effects of growth hormone on development of acute lymphoblastic leukaemia. Lancet 2, 434–435 (1977)PubMedCrossRefGoogle Scholar
  174. 174.
    Rudali, G., Apiou, F., Muel, B.: Mammary cancer produced in mice with estriol. Eur. J. Cancer 11, 39–41 (1975)PubMedCrossRefGoogle Scholar
  175. 175.
    Russfield, A. B.: Tumors of Endocrine Glands and Secondary Sex Organs. Washington, D.C.: USPHS, Department HEW, 1966Google Scholar
  176. 176.
    Rustia, M., Shubik, P.: Transplacental effects of diethylstilbestrol on the genital tract of hamster offspring. Cancer Lett. 1, 139–146 (1976)CrossRefGoogle Scholar
  177. 177.
    Schaffer, A. J., Avery, M. E.: Diseases of the Newborn. Third Edition. Philadelphia: Saunders, 1971Google Scholar
  178. 178.
    Schardein, J. L., Kaump, D. H., Woosley, E. T., Jellema, M. M.: Long-term toxicologic and tumorigenesis studies on an oral contraceptive agent in albino rats. Toxicol. Appl. Pharmacol. 16, 10–23 (1970)PubMedCrossRefGoogle Scholar
  179. 179.
    Scheike, O.: Male breast cancer. Acta Pathol. Microbiol. Scand., Section A, Suppl. 251, 13–35 (1975)Google Scholar
  180. 180.
    Schindler, A. E.: Steroid metabolism of fetal tissues. II. Conversion of androstenedione to estrone. Am. J. Obstet. Gynecol. 123, 265–268 (1975)PubMedGoogle Scholar
  181. 181.
    Schneider, S. L., Alks, V., Morreal, C. E., Sinha, D. K., Dao, T. L.: Estrogenic properties of 3,9-dihydroxybenz[a]anthracene, a potential metabolite of benz[a]anthracene. J. Natl. Cancer Inst. 57, 1351–1354 (1976)PubMedGoogle Scholar
  182. 182.
    Schoenberg, B. S., Christine, B. W., Whisnant, J. P.: Nervous system neoplasms and primary malignancies of other sites. Neurology 25, 705–712 (1975)PubMedGoogle Scholar
  183. 183.
    Schoenberg, B. S., Greenberg, R. A., Eisenberg, H.: Occurrence of certain multiple primary cancers in females. J. Natl. Cancer Inst. 43, 5–32 (1969)Google Scholar
  184. 184.
    Schoental, R.: Carcinogenic hazards of estrogens. In: Multiple Primary Malignant Tumours. Severi, L. (Ed.). Perugia: Division of Cancer Research, 1974, p. 1003Google Scholar
  185. 185.
    Shain, S. A., McCullough, B., Segaloff, A.: Spontaneous adenocarcinoma of the ventral prostate of aged A X C rats. J. Natl. Cancer Inst. 55, 177–180 (1975)PubMedGoogle Scholar
  186. 186.
    Shimkin, M. B., Grady, H. G.: Toxic and carcinogen effects of stilbestrol in strain C3H male mice. J. Natl. Cancer Inst. 2, 55–60 (1941)Google Scholar
  187. 187.
    Shimkin, M. B., Grady, H. G., Andervont, H. B.: Induction of testicular tumors and other effects of stilbestrol-cholesterol pellets in strain C mice. J. Natl. Cancer Inst. 2, 65–80 (1941)Google Scholar
  188. 188.
    Silverberg, S. G., Makowski, E. L.: Endometrial carcinoma in young women taking oral contraceptive agents. Obstet. Gynecol. 46, 503–506 (1975)PubMedGoogle Scholar
  189. 189.
    Smith, D. C., Prentice, R., Thompson, D. J., Herrmann, W. L.: Association of exogenous estrogen and endometrial carcinoma. New Engl. J. Med. 293, 1164–1167 (1975)PubMedCrossRefGoogle Scholar
  190. 190.
    Smith, O. W., Smith, G. V. S., Hurwitz, D.: Increased excretion of pregnanediol in pregnancy from diethylstilbestrol with special reference to the prevention of late pregnancy accidents. Am. J. Obstet. Gynecol. 51, 411–415 (1946)PubMedGoogle Scholar
  191. 191.
    Smith, R. L.: Biliary excretion and hepatotoxicity of contraceptive steroids. Acta Endocrinol. Suppl. 185, 149–168 (1974)Google Scholar
  192. 192.
    Smithline, F., Sherman, L., Kolodny, H. D.: Prolactin and breast carcinoma. New Engl. J. Med. 292, 784–792 (1975)PubMedCrossRefGoogle Scholar
  193. 193.
    Snell, K. C.: Spontaneous lesion of the rat. In: Pathology of Laboratory Animals. Ribelin, W. E., McCoy, J. R. (Eds.). Springfield: Charles C. Thomas, 1965, p. 266Google Scholar
  194. 194.
    Song, C. S., Kappas, A.: The influence of hormones on hepatic function. In: Progress in Liver Diseases, 1971, Vol. 3, p. 89Google Scholar
  195. 195.
    Stangel, J. J., Innerfield, I., Reyniak, J. U., Stone, M. L.: The effect of conjugated estrogens on coagulability in menopausal women. Obstet. Gynecol. 49, 314–316 (1977)PubMedGoogle Scholar
  196. 196.
    Stumpf, W. E., Sar, M., Aumüller, G.: The heart: A target organ for estradiol. Science 196, 319–321 (1977)PubMedCrossRefGoogle Scholar
  197. 197.
    Suntzeff, V., Burns, E. L., Moskop, M., Loeb, L.: On the proliferative changes taking place in the epithelium of vagina and cervix of mice with advancing age and under influence of experimentally administered estrogenic hormones. Am. J. Cancer 32, 256–289 (1938)PubMedGoogle Scholar
  198. 198.
    Sweeney, E. C., Evans, D. J.: Hepatic lesions in patients treated with synthetic anabolic steroids. J. Clin. Pathol. 29, 626–633 (1976)PubMedCrossRefGoogle Scholar
  199. 199.
    Symmers, W. St. C.: Carcinoma of breast in trans-sexual individuals after surgical and hormonal interference with the primary and secondary sex characteristics. Br. Med. J. 2, 83–85 (1968)PubMedCrossRefGoogle Scholar
  200. 200.
    Tausk, M.: Pharmacology of Hormones. Stuttgart: Georg Thieme Publishers, 1975Google Scholar
  201. 201.
    Thomas, B. L.: Methadone-associated gynecomastia. New Engl. J. Med. 294, 169 (1976)PubMedGoogle Scholar
  202. 202.
    Thompson, E. B.: The cellular actions of glucocorticoids in relation to human neoplasms. Curr. Top. Mol. Endocrinol. 4, 114–132 (1976)PubMedGoogle Scholar
  203. 203.
    Tormey, D. C., Waalkes, T. P., Simon, R. M.: Biological markers in breast cancer. II. Clinical correlations with human chorionic gonadotropin. Cancer 39, 2391–2396 (1977)PubMedCrossRefGoogle Scholar
  204. 204.
    Veterans Administration Cooperative Urologic Research Group: Treatment and survival of patients with cancer of the prostate. Surg. Gynecol. Obstet. 124, 1011–1017 (1967)Google Scholar
  205. 205.
    Vischer, E., Wittstein, A.: Enzymic transformation of steroids by microorganisms. In: Advances in Enzymology and Related Subjects of Biochem. New York: Interscience 1958, Vol. XX, p. 237Google Scholar
  206. 206.
    Wade, N.: Anabolic steroids: Doctors denounce them, but athletes are not listening. Science 176, 1399–1403 (1972)PubMedCrossRefGoogle Scholar
  207. 207.
    Watrous, R. M., Olsen, R. T.: Diethylstilbestrol in industry: A test for early detection as an aid in prevention. Am. Ind. Hyg. Assoc. J. 20, 469–472 (1959)PubMedCrossRefGoogle Scholar
  208. 208.
    Wilson, J. D.: Recent studies on the mechanism of action of testosterone. New Engl. J. Med. 287, 1284–1291 (1972)PubMedCrossRefGoogle Scholar
  209. 209.
    World Health Organization Information Bulletin on the Survey of Chemicals Being Tested for Carcinogenicity. No. 7. Lyon: IARC, 1978Google Scholar
  210. 210.
    Wynder, E. L., Mabuchi, K., Whitmore, W. F.: Epidemiology of cancer of the prostate. Cancer 28, 344–360 (1971)PubMedCrossRefGoogle Scholar
  211. 211.
    Zackheim, H. S.: Effect of castration of the induction of epidermal neoplasms in male mice by topical methylcholanthrene. J. Invest. Dermatol. 59, 479–482 (1970)CrossRefGoogle Scholar
  212. 212.
    Ziel, H. K., Finkle, W. D.: Increased risk of endometrial carcinoma among users of conjugated estrogens. New Engl. J. Med. 293, 1167–1170 (1975)PubMedCrossRefGoogle Scholar
  213. 213.
    Zumoff, B., Fishman, J., Cassouto, J., Hellman, L., Gallagher, T. F.: Estradiol transformation in men with breast cancer. J. Clin. Endocrinol. 26, 960–966 (1966)CrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin · Heidelberg 1979

Authors and Affiliations

  • Carolyn H. Lingeman

There are no affiliations available

Personalised recommendations